Information Provided By:
Fly News Breaks for February 27, 2020
Feb 27, 2020 | 18:36 EDT
Piper Sandler analyst Christopher Raymond keeps his Overweight rating and $60 price target on Aimmune, saying there is no change to his positive view on the company after its Q4 results. With the approval of Parforzia in hand, the analyst anticipates a "meaningful short squeeze" to play out over the next 12 months given that the pre-launch prescriber enthusiasm appears to be both robust and accelerating.
News For AIMT From the Last 2 Days
There are no results for your query AIMT